At the risk of not following my own advice re ignoring rolling, let me just add a comment about the hollowness of rolling's comment that "EMV may have a great product but it may not be a good business".
His/her whole argument is based on the naive comment that a lack of institutions joining the register equates to 'not being a good business'. Well, of course, this is true of every company that has ever listed in their start-up phase, even the Apples and Microsofts. It is a non-argument.
If rolling really wants to mount an argument that EMV is 'not a good business' it needs to address the claim in terms of issues with management quality, business model and structure, quality of staff, networking, business rollout, collaborations and product marketability.
On all these matters, EMV appears to be thriving. That is clear in the progress to date, meeting of all milestones, the calibre of recruits and partnerships, the amount of management skin in the game, the absence of staff turnover and the highly professional approach to updating the market.
In fact, rolling, him or herself, captured it perfectly in his/her post on 10 July 2019, as follows:
"They are a smart bunch at EMV. It would be silly to bet against them.
Surround your money with smart people is good investment advice I think".
So what has happened, since Jul 2019, to change rolling's mind? Nothing I would think except an unethical strategy to acquiring more shares.
It is quite clear, conversely, that the business has strengthened enormously since Jul 2019, with these key developments, for example:
1. Several Advance Qld Fellowships
2. Successful pilot trial of the Gen 1 device
3. Partnership with ASA established
4. $15.5M in grants (MRFF, MMI and Medical Devices Fund)
5. Appointment of Ron Weinberger as MD
6. Recruitment of high quality technical, regulatory and product development teams (drawing many of them from high calibre medtech companies)
7. Appointment of highly experience Phillip Dubois to the board
8.Appointment of Professor Stuart Crozier to position of Chief Scientist
9. Establishment of clinical research partnerships with leading hospitals (Princess Alexandra, Liverpool and Melbourne)
10. Appointment og global leading Professors Donnan and Davis to the Clinical Advisory Board
11. Strategic Agreement with global leading VNA developer, Keysight Technologies
12. On-going research collaborations with Uni of Queensland
13. Timely commencement of Pivotal trial following Ethics approval and green light from leading hospitals
Enough said!
Expand
(20min delay)